Traditional hospital factors-such as case volume and academic status-do not appear to predict whether patients with cardiac arrest at that facility are likely to experience delays in receiving defibrillation, according to a report in the July 27 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. The American Heart Association recommends that defibrillation be performed within two minutes of cardiac arrest, according to background information in the article. Longer delays to defibrillation are associated with lower survival rates following cardiac arrest in the hospital. Previous studies have found that factors associated with individual patients, such as being admitted to the hospital for a non-cardiac diagnosis and experiencing cardiac arrest on evenings and weekends, predicted delayed defibrillation.
Scientists in the US suggest that current tests for diagnosing ovarian cancer are not good enough and we need to develop better ways of detecting the disease much earlier. The study is published on 28 July in the open access journal Public Library of Science and is the work of researchers from Stanford University School of Medicine and the non-profit Canary Foundation, an organization dedicated to the early detection of many types of cancer. The idea of ovarian cancer scares women and their doctors because it is so hard to detect in the early stages. The National Cancer Institute (NCI) suggests that estimates show that 21, 550 women will be diagnosed with ovarian cancer and 14, 600 women will die of the disease in 2009.
Nationally, about ten percent of women in the US are recalled for a second mammogram after an abnormality is detected on the first one - for most women this can be very stressful. However the use of digital breast tomosynthesis and full-field digital mammography combined may be associated with a substantial decrease in recall rate, according to a study performed at UPMC in Pittsburgh, PA. Some researchers believe that digital breast tomosynthesis depicts the breast tissue in a way which may allow radiologists to identify some tumors which could be missed with standard two-dimensional mammography. The study included 125 patients that were evaluated using a combined method of digital breast tomosynthesis and standard digital mammography.
Terumo Cardiovascular Systems (Terumo CVS) announced that it has initiated a Phase II Clinical Trial for the Anaconda(TM) AAA (Abdominal Aortic Aneurysm) Stent Graft System in the U.S. The Anaconda system is manufactured by Scotland-based Terumo subsidiary Vascutek Ltd. The first U.S. implant was performed on June 8th at Arizona Heart Hospital by the principal investigator, Julio Rodriguez-Lopez, M.D. The objective of the Vascutek Anaconda Stent Graft System Phase II IDE Study (G030036) is to assess the safety and effectiveness of the Anaconda stent graft system in patients presenting with AAA when compared to historical open surgical repair.
CNN reports that African Americans and whites are treated differently by doctors. "While it's extremely difficult to tell in any given situation how much race -- consciously or unconsciously -- plays a role in a doctor's decision making, multiple studies over several decades have found doctors make different decisions for black patients and white patients even when they have the same medical problems and the same insurance." For example, "In a study conducted in 2007, Harvard researchers showed doctors a vignette about a 50-year-old man with chest pain who arrived at the emergency room, where an EKG showed he'd had a heart attack. Sometimes the researchers paired the medical history with a photo of black man and other times with a photo of a white man.
AccuVein LLC, maker of the AV300, the world's first hand-held, non-contact vein illumination device, announced today that its medical device now carries a CE Mark, enabling the Company to commence European sales of AccuVein's AV300. "Receiving approval to ship the AV300 to Europe is an important step in bringing this beneficial device to healthcare practitioners around the globe, " said Stephen P. Conlon, President of AccuVein. "Furthermore, Europe provides a significant growth opportunity for AccuVein allowing us to build upon our successful launch in the United States." AccuVein recently achieved an International Organization for Standardization (ISO) 13485 Certification, acknowledging that its quality management processes meet international standards.